52-week efficacy and safety profile of alglucosidase alfa produced at 4000 liter scale in US patients with Pompe disease: ADVANCE, a phase 4 open-label prospective study

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Hahn, S; Pena, L; Day, JW; Gambello, M; Gibson, JB; Hillman, R; Kronn, D; Stockton, D; Leslie, N; Tanpaiboon, P; Wang, R; Haack, KA; Sparks, S; Zhao, Y; Kishnani, PS

Published Date

  • February 2016

Published In

Volume / Issue

  • 117 / 2

Start / End Page

  • S54 - S54

Published By

International Standard Serial Number (ISSN)

  • 1096-7192

Digital Object Identifier (DOI)

  • 10.1016/j.ymgme.2015.12.281